| abstract |
The present invention relates to Pim kinase inhibitor compounds which can be used alone or in combination of pharmaceuticals. One such combination is a combination of (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and, optionally, at least one pharmaceutical acceptable salt, for simultaneous, separate or sequential use, particularly for the treatment of a myelogenous neoplasm or leukemia. ; A pharmaceutical composition comprising such a combination; The use of such a combination for the manufacture of a medicament for the treatment of a myelogenous neoplasm or leukemia; A commercial package or product comprising such a combination as a combination preparation for simultaneous, separate or sequential use; And methods of treating mammals, particularly humans. |